Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc-dependent dehydrogenase NcLAD, specifically known as L-arabinitol dehydrogenase from the filamentous fungus Neurospora crassa, is a key enzyme in the fungal pentose catabolic pathway (UniProt Q7S9L8). It catalyzes the NAD+-dependent oxidation of L-arabinitol to L-xylulose, which is a critical step for the utilization of L-arabinose as a carbon source (Nocek et al., 2011). Structurally, NcLAD belongs to the medium-chain dehydrogenase/reductase (MDR) family and requires a zinc ion for its catalytic activity. While not a primary therapeutic target for human diseases, NcLAD is of significant interest in industrial biotechnology and metabolic engineering for the production of biofuels and biochemicals from lignocellulosic biomass. Its well-characterized structure and kinetics make it a model for understanding polyol metabolism in fungi. The enzyme's specificity and efficiency are key factors in designing microbial cell factories for sustainable chemical production.
Catalyzes the NAD+-dependent oxidation of L-arabinitol to L-xylulose.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-arabinitol dehydrogenase (Neurospora crassa) (NcLAD).